One of Our Clinical Studies Could Be Right For You!
We have ongoing studies for Alzheimer's Disease, Parkinson's Disease and Depression. You could be part of the solution. Submit this form to see if qualify for one of our trials.
Current drug development for Alzheimer's Disease targets three main stages of the disease. We are enrolling studies for all three stages.
Preclinical Alzheimer's Disease
It is estimated that 1 in 3 individuals above the age of 60 carries the toxic beta amyloid proteins (plaques), which start the brain damage in AD. This process of brain damage can go on silently with no outward symptoms for 15-20 years before the first symptoms manifest.
At this stage, there are no symptoms of memory or functional loss. Individuals with a family history of AD or who wonder/worry if they have AD are welcome to screen for our preclinical studies.
Mild Cognitive Impairment (MCI or Early AD)
The first symptoms of AD are just mundane, everyday forgetfulness, which is often dismissed as “just a senior moment.” Individuals in this stage are still independent and functional with routine tasks and do remember important events. They often feel their brain is not as sharp as before.
Common Symptoms of MCI include:
- Repeating stories and conversations without being aware of it
- Asking the same questions over and over
- Forgetting events and conversations, tasks and errands
- Needing more reminders with cell phones and notes
- Struggling with multistep tasks and learning new tasks
Keystone Clinical Studies is working with medications targeted against the amyloid plaques and tau tangles that cause the brain damage of AD.
Early Alzheimer's Dementia
At this stage, individuals need help from family members for activities of daily living, mostly in the form of prompts and reminders. They are not able to safely drive, manage money, or navigate complex social interactions. Individuals with early Alzheimer's dementia often need assisted living level of care. They do not require 24 hour supervision or nursing home level of care.
Medications for individuals at this stage are targeted towards neuro-regeneration, which is hoped to slow or stop the decline.
Studies for all stages start with a state of the art diagnostic work up, which could include specialized blood tests, an MRI to rule out other causes of memory loss, and PET scans to detect amyloid and/or tau particles. These tests are generally not available in clinical practice. If the results are suggestive of AD, individuals could receive study medication targeted at the disease process. Ongoing medical and neuro-psychiatric monitoring is part of all studies.
We Are Currently Enrolling for
Alzheimer's Disease Clinical Studies.
Major Depressive Disorder (MDD), also known as “clinical depression” is the most common type of depression. MDD is typically more severe and interferes with daily functioning more so than depression caused by a loss or related to a medical condition.
Common Symptoms of MDD include:
- Feelings of sadness/depressed most of the day, every day
- Feeling anxious or panicked
- Pessimism and/or hopelessness
- Loss of interest in usual hobbies or activities
- Increased irritability
- Difficulty concentrating or indecisiveness
- Fatigue or loss of energy
- Persistent aches, pains, and/or digestivevissues
- Loss of appetite or overeating
- Changes in usual sleep patterns (sleeping too much or too little)
- Thoughts of suicide
Treatment for MDD includes taking antidepressant medication. While antidepressants do help many patients, as many as two thirds of individuals do not achieve a full resolution of symptoms even after being on medication for 6-8 weeks. Keystone Clinical Studies is working on several medications that work differently than typical antidepressants, and may provide faster and more complete relief of depressive symptoms. To learn more or see if you qualify for a study, click here.
If you are experiencing suicidal thoughts or need help immediately, please call 988 to reach the National Suicide Prevention Lifeline or go to suicidepreventionlifeline.org
Parkinson's Disease (PD) is a progressive, neurological disorder that affects movement and is accompanied by tremors. During the progression of the disease, many individuals experience cognitive dysfunction which leads to dementia in the later stages of PD. It is estimated that up to 80% of individuals with PD develop dementia. There is currently no cure for PD dementia, and available medications aim to manage or improve symptoms only.
Keystone Clinical Studies is working on a medication to potentially slow the progression of dementia associated with PD. Contact us for more information.